Skip to main content

01.12.2018 | Research | Ausgabe 1/2018 Open Access

Critical Care 1/2018

Early therapeutic plasma exchange in septic shock: a prospective open-label nonrandomized pilot study focusing on safety, hemodynamics, vascular barrier function, and biologic markers

Critical Care > Ausgabe 1/2018
Hannah Knaup, Klaus Stahl, Bernhard M. W. Schmidt, Temitayo O. Idowu, Markus Busch, Olaf Wiesner, Tobias Welte, Hermann Haller, Jan T. Kielstein, Marius M. Hoeper, Sascha David
Wichtige Hinweise

Electronic supplementary material

The online version of this article (https://​doi.​org/​10.​1186/​s13054-018-2220-9) contains supplementary material, which is available to authorized users.
Hannah Knaup and Klaus Stahl contributed equally to this work.
A comment to this article is available online at https://​doi.​org/​10.​1186/​s13054-018-2286-4.
Acute Physiology and Chronic Health Evaluation
Cytometric bead array
Cardiac index
C-reactive protein
Electric cell-substrate impedance sensing
Fluorescence-activated cell sorting
Fresh frozen plasma
Global end-diastolic volume index
Human umbilical vein endothelial cell
Intensive care unit
International normalized ratio
Mean arterial pressure
Randomized controlled trial
Renal replacement therapy
Sequential Organ Failure Assessment
Soluble receptor of tyrosine kinase with immunoglobulin-like and EGF-like domains 2
Systemic vascular resistance index
Stroke volume variance
Transendothelial electrical resistance
Therapeutic plasma exchange
Vascular endothelial growth factor
von-Willebrand factor
White blood cell


Sepsis is defined as life-threatening organ dysfunction caused by a dysregulated host response to infection; if hypotension is refractory to volume resuscitation and serum lactate is elevated it is termed septic shock [ 1]. In the absence of a specific intervention other than anti-infective drugs, mortality rates can still be as high as 60% [ 2]. The overwhelming host response is a key driver of morbidity and mortality [ 3]. Despite our increasing understanding of the molecular and pathophysiological processes underlying sepsis-associated organ injury, treatment options are all nonspecific with regard to the host response [ 4]. There is an unmet need to improve our therapeutic strategies by directly targeting and modulating the pathological response of the host. Part of the failure to develop effective strategies might be attributable to the complexity and nonlinearity of sepsis pathophysiology making it unlikely for a single specific agent to successfully influence the host response in its whole nature [ 5, 6].
The theoretical concept of therapeutic plasma exchange (TPE) in sepsis combines two major aspects in one intervention: 1) removal of harmful circulating molecules (as part of the injurious cytokine storm) that directly contribute to the manifestation of the disease; and 2) replacement of protective plasma proteins that compensate for the loss of factors important for coagulation (e.g., activated protein C, antithrombin, tissue factor pathway inhibitor), fibrinolysis (e.g., von Willebrand factor (vWF) cleaving proteases), and that counteract inflammation and vascular leakage (e.g., angiopoietin-1, vascular endothelial growth factor (VEGF)) to ultimately restore hemostasis [ 7].
So far, the available data on TPE in sepsis are poor compared with other blood purification techniques (summarized in [ 8]); mostly, case reports (e.g., [ 9]) and uncontrolled retrospective studies [ 10, 11] have been published. A recent meta-analysis found only two single-center randomized controlled trials (RCTs) in adults in which a reduced mortality (risk ratio (RR) 0.63, 95% confidence interval (CI) 0.42 to 0.96) was reported [ 12]. The largest RCT showed a promising trend towards improved survival [ 13]. The American Society for Apheresis (ASFA) stated in their 2016 guidelines “the optimum role of apheresis therapy is not established; decision making should be individualized”, and gave a weak recommendation [ 14].
We hypothesized that TPE as an additive treatment might modulate the deleterious host response in a comprehensive approach affecting hemodynamics, fluid balances, vascular barrier function, and cytokine profiles in the most critical septic shock patients if applied at the earliest possible time point. Therefore, we designed this exploratory study to demonstrate the safety and feasibility with regard to recruitment and enrollment for a larger RCT, and to secondarily test preliminary efficacy with regard to the abovementioned hemodynamics and biochemical markers.


Study population

This was a prospective single-center, open-label, nonrandomized pilot study. We screened 807 patients submitted to our 14-bed medical intensive care unit (ICU) from July 2016 to July 2017 for the presence of sepsis as per the SEPSIS-3 definition [ 1] (Fig.  1). All patients were treated according to the 2012 Surviving Sepsis Campaign (SSC) guidelines [ 15]. The ethics committee of Hannover Medical School approved the protocol (no. 2786–2015), and written informed consent was obtained from participants or authorized representatives. The study was performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.

Inclusion and exclusion criteria

Patients were included based on: 1) septic shock with the need for vasopressors < 12 h prior to entry; and 2) profound systemic hypotension requiring norepinephrine (NE) doses of > 0.4 μg/kg/min despite adequate intravenous fluid resuscitation (≥ 30 mL/kg bodyweight crystalloids). TPE had to be initiated within 6 h after study inclusion. For exclusion criteria, we used pregnancy or breast feeding, age < 18 years, end-stage chronic disease, and the presence of a directive to withhold life-sustaining treatment.

Therapeutic plasma exchange (TPE)

Vascular access was established by venous insertion of an 11-French two-lumen hemodialysis catheter. Based on previous experience we decided to use one TPE since hemodynamic improvements were only achieved by the very first exchange (data not shown). TPE was performed against fresh frozen plasma (FFP), exchanging 1.2× the individually calculated plasma volume with a blood flow of 60 (55–63) mL/min. Anticoagulation during TPE was achieved by regional citrate infusion. In patients with acute kidney injury, dialysis was interrupted for the duration of TPE (110 (93–120) min). Blood samples were drawn immediately before and after TPE. Patients were closely followed for the next 28 days and survival was recorded. NE dose was titrated every 10–15 min to achieve a mean arterial pressure (MAP) above 65 mmHg.
The primary aim of this study was to evaluate the safety and feasibility with regard to recruitment and enrollment within 12 h of shock for a planned RCT ( NCT03065751) that would allow us to investigate hard clinical endpoints.
In addition, preliminary efficacy was evaluated by longitudinal assessment before and after TPE for:
  • NE dose to maintain MAP ≥ 65 mmHg
  • MAP
  • 6-h fluid balances
  • C-reactive protein (CRP), procalcitonin (PCT), white blood cell (WBC) counts
  • International normalized ratio (INR), platelets
  • cytokines (interleukin (IL)-6, IL-1b, IL-8, and IL-10)
  • permeability-regulating factors (angiopoietin-1, -2, and soluble receptor of tyrosine kinase with immunoglobulin-like and EGF-like domains 2 (sTie2))
  • preload (stroke volume variance (SVV) and global end-diastolic volume index (GEDI))
  • afterload (systemic vascular resistance index (SVRI))
  • cardiac index
Furthermore, 28-day survival was analyzed for the whole cohort and for subgroups (immediate and sustained responders); immediate response to TPE was defined as a reduction of the NE > 20% from baseline immediately following completion of TPE, and sustained response was described as any reduction of Sequential Organ Failure Assessment (SOFA) score within 48 h post-TPE, as described previously [ 16].

Endothelial ex-vivo stimulation with plasma from septic shock patients

We used human umbilical vein endothelial cells (HUVECs) that were isolated from umbilical vein donors (ethical improvement no. 1303–2012) and cultured as described previously [ 17]. To mimic the septic vascular phenotype in confluent HUVEC monolayers, their growth medium was supplemented with 5% plasma obtained from septic patients within minutes before and after TPE.

Fluorescent immunocytochemistry

Thirty minutes after treatment with patient plasma, cells were fixed in 2.5% paraformaldehyde, permeabilized, and incubated with primary antibody (VE-cadherin; BD Bioscience, San Diego, CA), followed by with secondary Alexa-antibody and phalloidin [ 18].

Transendothelial electrical resistance (TER)

To quantify endothelial permeability, serial TERs were recorded with an electric cell-substrate impedance sensing (ECIS) approach in triplicate (Ibidi, Applied BioPhysics Inc.) as described previously [ 19].

Measurement of circulating cytokines and permeability factors

Angiopoietin-1, -2, and sTie2 were measured by enzyme-linked immunosorbent assays (ELISAs; R&D systems, Minneapolis) and a panel of cytokines was assessed by cytometric bead array (CBA; BD Bioscience) on a fluorescence-activated cell sorting (FACS) platform.

Statistical analysis

Date are presented as median (25% to 75% interquartile range (IQR)). Two-tailed p values of less than 0.05 were considered to indicate statistical significance. Paired t test or Wilcoxon test (for non-normally distributed variables) was utilized to compare longitudinal values before (pre-) and after (post-) TPE. Survival data were analyzed by log-rank test and visualized by Kaplan-Meier curves. We compared the subgroups of responders and nonresponders utilizing a Mann-Whitney U test for nominal variables and performing a χ 2 test for categorical variables. We used GraphPad Prism 7 (La Jolla, CA) and SPSS Statistics (IBM) for data analysis and graph generation.


Cohort characterization

Demographic and clinical details are summarized in Table  1. Sixty-five percent of the patients were men, and the median age was 52 (30–58) years. The lungs and the abdomen were the most common sites of infection. A causative pathogen was identified in 75% of the cases. All patients were treated with a combination of broad-spectrum antibiotics. Retrospectively, 95% of the initial treatment strategies were sensitive to the later identified microbial. Patient 9 had a positive blood culture for Candida that was not covered initially (Additional file  1: Table S1). Immediately after TPE was performed, all patients received an additional full dose of antibiotics.
Table 1
Demographic and clinical characteristics at baseline
Age (years)
52 (30–58)
Sex (male/female), n (%)
13/7 (65/35)
Weight (kg)
85 (71–103)
Height (m)
1.79 (1.7–1.85)
BMI (kg/m 2)
26.9 (22.2–31.9)
Sepsis onset, n (%)
10 (50)
10 (50)
Site of infection, n (%)
11 (55)
3 (15)
1 (5)
 Soft tissue
3 (15)
1 (5)
1 (5)
Pathogen, n (%)
3 (15)
5 (25)
1 (5)
5 (25)
 Not identified
6 (30)
40.5 (35–46)
18 (16–20)
ADAMTS13 (%)
44 (29–56.5)
Norepinephrine dose (μg/kg/min)
0.82 (0.61–1.17)
Mechanical ventilation, n (%)
19 (95)
Oxygenation index (PaO 2/FiO 2)
132 (96–229)
Renal replacement therapy, n (%)
13 (65)
Organ failure, n (%)
19 (95)
14 (70)
10 (50)
20 (100)
19 (95)
16 (80)
Multi organ failure, n (%)
0 (0)
1 (5)
6 (30)
7 (35)
6 (30)
Immunosuppression, n (%)
13 (65)
Values are shown as median (interquartile range) unless otherwise indicated
ADAMTS13 A disintegrin and metalloprotease with thrombospondin-1-like domains 13, APACHE Acute Physiology and Chronic Health Evaluation, BMI body mass index, SOFA Sequential Organ Failure Assessment
Median (IQR) Acute Physiology and Chronic Health Evaluation (APACHE) II and SOFA scores were 40.5 (35.0–46.0) and 18 (16–20), respectively. Ninety-five percent of patients were mechanically ventilated and had an oxygenation index of 132 (96–229). Patients had at least three failed organ systems, while organ failure was defined as an organ-specific SOFA score of equal or more than 2. Acute kidney injury (AKI) with the need for renal replacement therapy (RRT) was present in 65% of the patients at inclusion.

Feasibility and safety

Based on the inclusion criteria that aimed at identifying the sickest patients (NE > 0.4 μg/kg/min) at a very early state (shock < 12 h) we included 24 out of 231 sepsis patients within 1 year (Fig.  1). We were able to perform TPE within 6 h after inclusion. We did not obtain complete plasma samples from four patients, so these were excluded. The TPE procedure was found to be safe. Earlier reported side effects such as hypotension and allergic reactions [ 12] were not observed in this study. Given the successful recruitment and safety in this pilot study, a multicenter RCT investigating TPE in septic shock with a hard primary endpoint appears feasible.

Immediate effects of TPE on clinical parameters

The dose of NE after a single TPE was significantly reduced (pre-TPE 0.82 (0.61–1.17) vs. post-TPE 0.56 (0.41–0.78) μg/kg/min, p = 0.0002; Fig.  2a). The MAP/NE ratios before and after TPE were 74.9 (48.5–116.8) and 114.3 (75.3–166.7) μg/kg/min/mmHg ( p < 0.0001; Fig.  2b), respectively. The longitudinal time course of NE doses during TPE is shown in Fig.  2c.
A subgroup of 10 patients had hemodynamic assessments performed by thermodilution (PiCCO®, Pulsion) (Additional file  2: Figure S1). Here, we observed a mild, but nonsignificant increase in cardiac index (2.85 (2.39–4.32) vs. 3.42 (2.71–5.19) L/min/m 2, p = 0.375) which was not attributable to an increased heart rate (111 (91–126) vs. 104 (87–119) beats/min, p = 0.107). Afterload as assessed by SVRI was not changed (1450 (980–1873) vs. 1520 (1060–2126) dyn/s/cm 5/m 2, p = 0.695), while SVV improved significantly (20 (12.5–29)% vs. 11 (6–14.5)%, p = 0.008; Fig.  2d). Fluid intake could be limited compared with a 6-h period before TPE (3411 (2295–4933) vs. 2190 (1431–4060) mL, p = 0.007; Fig.  2e). Clinical and biochemical changes are summarized in Table  2.
Table 2
Changes in clinical and biochemical parameters after TPE
Therapeutic plasma exchange (TPE)
p value
Clinical parameters
 MAP (mmHg)
65.5 (54.5–75.3)
69 (64–79.3)
 NE dose (μg/kg/min)
0.82 (0.61–1.17)
0.56 (0.41–0.78)
 MAP/NE (mmHg/μg/kg/min)
74.9 (48.5–116.8)
114.3 (75.3–166.7)
< 0.0001*
 HR (bpm)
110.5 (91.3–125.5)
103.5 (86.8–119)
 SVV (%)
20 (12.5–29)
11 (6–14.5)
 SVRI (dyne/s/cm 5/m 2)
1450 (980–1873)
1520 (1060-2126)
 SVRI/NE (dyne/s/cm 5/m 2)/(μg/kg/min)
1743 (1008-2921)
2547 (1213-3923)
 EVLWI (mL/kg)
14 (8–17)
11.5 (8–16.5)
 GEDI (mL/m 2)
670 (483–909)
755 (622–998)
 Cardiac index (L/min/m 2)
2.85 (2.39–4.32)
3.42 (2.71–5.19)
 Fluid balance/6 h (mL)
3411 (2295-4933)
2190 (1431-4060)
Gas exchange
 Oxygenation index (PaO 2/FiO 2)
132 (96–229)
115 (102–212)
 AaDO 2 (mmHg)
360 (251–541)
329 (247–489)
Inflammatory biomarkers
 CRP (mg/L)
236 (147–302)
174 (86–288)
 PCT (ng/mL)
24.1 (16.9–83.7)
31 (14.8–87.3)
 WBC (1/nL)
11.2 (0.93–34.8)
8.4 (1.2–25.6)
 PLT (1/nL)
43.0 (16.8–112)
34.0 (20–66)
1.76 (1.44–2.1)
1.43 (1.26–2.1)
Acid base balance
7.28 (7.19–7.34)
7.33 (7.23–7.38)
 pCO 2 (mmol/L)
44.5 (35.3–56.3)
46 (37–55)
 HCO 3 (mmol/L)
20.0 (17–23.8)
22.0 (20–24.7)
 Lactate (mmol/L)
6.5 (2.8–11.3)
6.5 (3.2–10.8)
 IL-8 (ng/mL)
1.35 (0.6–10.81)
1.09 (0.4–7.1)
 IL-1b (pg/mL)
147.1 (57.1–241.6)
92.2 (42.9–184.8)
 IL-6 (ng/mL)
10.8 (2.54–27.6)
4.6 (0.9–13.7)
 IL-10 (pg/mL)
143.3 (65.5–259.2)
98.1 (59.6–180.4)
Vasoactive substances
 Angiopoietin-1 (ng/mL)
3.27 (2.01–5.36)
2.97 (1.42–5.15)
 Angiopoietin-2 (ng/mL)
9.51 (5.06–13.2)
5.14 (3.04–11.18)
< 0.0001*
 sTie2 (ng/mL)
16.03 (10.91–19.51)
8.36 (6.67–12.85)
< 0.0001*
Values are shown as median (interquartile range)
AaDO 2 alveolar-arterial oxygen difference, CRP C-reactive protein, EVLWI extravascular lung water index, GEDI global end-diastolic index, HCO 3 arterial bicarbonate concentration, HR heart rate, IL interleukin, INR international normalized ratio, MAP mean arterial pressure, NE norepinephrine, pCO 2 arterial partial pressure of carbon dioxide, PCT procalcitonin, PLT platelet count, sTie2 soluble receptor of tyrosine kinase with immunoglobulin-like and EGF-like domains 2, SVRI systemic vascular resistance index, SVV stroke volume variance, WBC white blood cell count
*Significant p values

Effects of TPE on biochemical parameters, circulating cytokines, and vasoactive substances

Humoral markers of inflammation were elevated in all patients, but did not change after TPE. Besides a reduction in cytokines known for their involvement in the pathophysiology of sepsis (e.g., IL-1b 147.1 (57.1–241.6) vs. 92.2 (42.9–184.8) pg/mL, p = 0.01; Table  2), we also observed reductive effects on permeability-inducing factors such as angiopoietin-2 (9.5 (5.1–13.2) vs. 5.1 (3.1–11.2) ng/mL, p < 0.0001). On the other hand, the antipermeability factor angiopoietin-1 (3.27 (2.01–5.36) vs. 2.97 (1.42–5.15) ng/mL, p = 0.1) was unchanged after TPE. The anti-inflammatory cytokine IL-10 (143.3 (65.5–259.2) vs. 98.1 (59.6–180.4) pg/mL, p = 0.05) was slightly reduced after TPE, although this did not reach statistical significance (Table  2).
In addition, we observed an improved acid-base balance, although continuous RRT that had been started in 65% of the patients before TPE was discontinued during the time of TPE (pH 7.28 (7.19–7.34) vs. 7.33 (7.23–7.38), p = 0.01).

Predictors of responsiveness to TPE

To identify potential predictors of TPE responsiveness, we defined two types of responses: immediate (reduction of the NE dose > 20%) and sustained (any reduction in SOFA score within 48 h) in accord with the literature [ 16]. Fifty percent of patients (10/20) were immediate responders and 35% (7/20) were sustained responders. Subgroup analyses in each group were performed for numerous baseline characteristics (Additional file  3: Table S2). However, multivariable regression analysis could not identify independent predictors of acute or sustained TPE responsiveness.

Effect on 28-day mortality

The observed 28-day mortality was 65% (Fig.  3a). Median 28-day survival was 14.5 days. In the “immediate-responder” group, mortality was 60% and median 28-day survival was 22.5 days; mortality in the “nonresponder” group was 70% and median 28-day survival 8 days (HR (hazard ratio) 0.69; 95% CI 0.23 to 2.06; p = 0.38; Fig.  3b). In the “sustained-responder” group, mortality was 43% and median 28-day survival was 28 days; mortality in the “nonresponder” group was 77% and median 28-day survival was 8 days (RR 0.41; 95% CI 0.14 to 1.22; p = 0.137; Fig.  3c).

Effect on vascular barrier function: ex-vivo analysis

We exposed HUVECs to plasma before and after TPE and assessed their phenotype by fluorescent immunocytochemistry. Cell-cell contacts were analyzed by the adherens junction protein VE-cadherin (green) whereas the cytoskeletal architecture was visualized by F-actin (red). Septic shock plasma induced the formation of focal adhesions, actin stress fibers, and multiple paracellular gaps, changes not observed when the experiment was performed with plasma that was obtained from the same patient, but 15 min after TPE (Fig.  4a). We additionally performed a quantitative functional assay by measuring the TER (i.e., the permeability) in real time. This method revealed that 60.0% of patients’ plasma showed improvements (Fig.  4b) whereas 40% of patients’ plasma showed no change in its permeability-inducing capacity (Fig.  4c). We grouped the patients according to their response in the ECIS assay and found that the mortality in the ECIS response group was 58.4% whereas it was 75% in the ECIS nonresponsive group.


This prospective, nonrandomized, single-center explorative study examined the feasibility and preliminary efficacy of TPE as an additive treatment strategy in septic shock. In summary, we found the following:
  • feasibility and safety of the procedure
  • hemodynamic improvement indicated by a NE reduction often achieved within minutes after TPE start
  • improved preload and fluid balance possibly due to a protective effect on vascular permeability
  • decline in plasma concentrations of proinflammatory mediators
  • reversibility of the septic endothelial phenotype ex vivo from 60% of patients plasma after TPE
A recent meta-analysis found four single-center RCTs that analyzed TPE in sepsis [ 12]. In adults, TPE was associated with a reduced mortality. The largest of those trials ( n = 106 patients) showed an encouraging trend towards improved survival (33.3% vs. 53.8%) [ 13]. Unfortunately, this study was underpowered and included a heterogeneous group of patients in terms of disease severity (< 60% with shock) and time of onset.
We believe that both timing and disease severity might be crucial for a beneficial effect of TPE. Therefore, we exclusively included patients that met the strict criteria with regard to onset (i.e. < 12 h) and severity (i.e. NE > 0.4 μg/kg/min) of shock. Before initiation of this study, we have occasionally treated sepsis patients with a particularly severe shock with TPE as rescue therapy. We routinely performed three TPEs on consecutive days but realized that hemodynamic improvements were only seen after the first (not the second or the third) treatment.
Under prospective study conditions, we could now collect data that might support our earlier encouraging observations. Ten out of 20 patients showed an immediate response, determined as a reduction of vasopressor > 20% and four patients showed a reduction of > 50%; one patient was even completely weaned off any vasopressors at the end of TPE. In 7 of 20 patients, an improvement in organ failure indicated by a SOFA score reduction was achieved within the first 48 h following TPE and this sustained response was also associated with a trend towards better survival. Unfortunately, we were not able to identify predictors of TPE responsiveness in this small cohort. Obviously, this study was neither designed nor powered to address the effects of TPE on survival. However, 65% of our patients died, underscoring both disease severity and also the fact that TPE does not provide a cure for septic shock, but potentially an adjunctive therapeutic option with beneficial effects.
A major difference between TPE and modern extracorporeal adsorption strategies [ 20] is based on the fact that the exchange of septic shock plasma with FFP might not lead to an unselective depletion of pro- and anti-inflammatory cytokines. It rather replenishes protective factors (within the FFPs) that had been consumed by the sepsis. Given the role of cytokines in the physiological host response to a local infection, a complete depletion of cytokines might not necessarily be beneficial per se. The exchange of septic against healthy plasma might be a procedure by which these circulating factors can be modulated but not completely removed. This hypothesis is supported by our findings with regard to the anti-permeability factor angiopoietin-1.
The beneficial effect of TPE on preload and fluid balance might reflect improved vascular barrier function. Alternatively, it is possible that the observed rapid hemodynamic stabilization was due to oncotic effects of the relatively large amount of FFPs that was substituted within 2 h during TPE. However, our cell culture studies are in line with the permeability hypothesis, as we found fewer endothelial alterations if the cells were challenged with plasma after TPE compared with the individual plasma before TPE.
This study has important limitations, mainly its small sample size, the single-center setting, and its nonrandomized nature. Given the lack of a control group, all positive effects observed during the course of TPE could have been unrelated to the intervention. In addition, the intervention was administered at a fixed dose, which precludes us from providing data on effects at different dosages or time frames. At inclusion to the study, 95% of patients were sedated and endotracheally intubated for mechanical ventilation. Their Glasgow Coma Score (GCS) at inclusion was therefore (artificially) determined to be 3 points. Using a GCS calculated at admission to the ICU (before sedation) would have yielded lower APACHE II scores. Unfortunately, we do not have this information from all patients and we wanted to reflect the baseline status at the inclusion time point. The NE cut-off of 0.4 μg/kg/min for inclusion is truly arbitrary and might not be optimal. The average NE doses of septic shock patients in many large-scale international RCTs is lower than our chosen 0.4 μg/kg/min (e.g., [ 2124]). However, some studies have also reported higher baseline NE requirements in septic shock [ 25]. The ideal NE dose to include the sickest septic shock patients has yet to be determined.
This explorative study was not designed to assess survival but to determine the feasibility and safety of a larger RCT and to assess preliminary efficacy. Given that we were able to enroll 20 patients within a year, we believe that such a multicenter RCT addressing clinical outcomes appears feasible.


Our exploratory study demonstrated preliminary safety and feasibility of TPE in early septic shock patients and we are currently preparing a randomized, controlled, multicenter study to further assess this treatment.


We highly appreciate the support and advice of Dr. Dieter Siebenlist and would like to thank Yvonne Nicolai for technical assistance with the endothelial cell culture.


Laboratory experiments were supported by a grant from the German Research Foundation to SD (DA1209/4–3).

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Ethics approval and consent to participate

The ethical committee of Hannover Medical School approved the protocol (no. 2786–2015), and written informed consent was obtained from participants or authorized representatives. The study was performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments. This study was designed to prove feasibility of a planned multicenter RCT ( NCT03065751).

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License ( http://​creativecommons.​org/​licenses/​by/​4.​0/​), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated.
Über diesen Artikel

Weitere Artikel der Ausgabe 1/2018

Critical Care 1/2018 Zur Ausgabe

Neu im Fachgebiet AINS

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update AINS und bleiben Sie gut informiert – ganz bequem per eMail.